Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Objective: Administration of infliximab is associated with a well-recognised risk of infusion
reactions. Lack of a mechanism-based rationale for their prevention, and absence of …

The treatment of inflammatory bowel disease (IBD)—ulcerative colitis (UC) and Crohn's
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …

Background and aims Immunogenicity with formation of anti-drug antibodies (ADA) to
biologics is an important reason for treatment failure in inflammatory bowel disease (IBD) …

Tumor necrosis factor (TNF) production is amplified in several autoimmune disorders. In the
1990s, it became a validated therapeutic target used for the treatment of conditions such as …

Background Formation of antibodies to infliximab (ATI) inversely correlates with functional
drug levels and clinical outcome. Comparison of drug levels and anti‐drug antibody …

Although tumor necrosis factor (TNF) antagonists have shown clear benefits over
conventional treatments for inducing and maintaining clinical remission in both Crohn's …

Perioperative hypersensitivity reactions (POH) constitute a clinical and diagnostic challenge,
a consequence of heterogeneous clinical presentations, and multiple underlying …

Background Whether infliximab therapy can be successfully discontinued after patients with
Crohn's disease have attained sustained, clinical, biochemical, and endoscopic remission is …

The clinical introduction of tumour necrosis factor (TNF) inhibitors has deeply changed the
treatment of inflammatory bowel diseases (IBD). It has demonstrated impressive efficacy as …